|
Clinical impact of medical policy supporting universal germline testing for patients with colorectal cancer. |
|
|
No Relationships to Disclose |
|
|
Employment - UnitedHealthcare |
Stock and Other Ownership Interests - UnitedHealthcare |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
Employment - United Health Group |
Stock and Other Ownership Interests - United Health Group |
Research Funding - Abbvie (Inst); Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Genentech/Roche (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst) |
|
|
|
Stock and Other Ownership Interests - Invitae |
|
|
Stock and Other Ownership Interests - United Health Group (I) |
|
|
Employment - United Health Group |
Stock and Other Ownership Interests - United Health Group |
|
|
|
|
Stock and Other Ownership Interests - Genome Medical; Invitae; Maze Therapeutics; Pfizer Pharmaceutical |
|
Consulting or Advisory Role - Genome Medical; Maze Therapeutics; Pfizer |
Patents, Royalties, Other Intellectual Property - Royalties on a patented mouse model for Parkinson disease held by the National Institutes of Health and the University of California San Francisco |
|
|
|
Stock and Other Ownership Interests - Invitae |